The global doxofylline syrup market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Doxofylline is generally used to treat asthma and other obstructive lung disorders such as chronic obstructive pulmonary disease (COPD). It is used to manage the symptoms such as wheezing, chest tightness, and shortness of breath associated with lung disorders. Doxofylline is a bronchodilator, that supports relaxing the smooth muscles of the airways in the lungs. The market growth is attributed to the better patient adherence, better taste of the syrup as compared to the tablet form of doxofylline as well as the novel innovations such as the addition of different flavors in the doxofylline syrup. The market growth is further attributed to the growing prevalence of cough, pulmonary disorders such as COPD, idiopathic pulmonary fibrosis, and lung cancer all over the globe.
Further, the switch from prescription to OTC category, and a rise in the geriatric population are anticipated to drive the demand for doxofylline syrup. Adding to this, the aging population (apart from the young children) is more prone to respiratory disorders such as asthma. For both these age groups where tablet swallowing could be a major challenge, syrups can prove to be an effective solution. This is one of the dominant factors which is driving the global doxofylline syrup market. Along with this, the surge in pipeline products is another major factor that drives the growth of the global doxofylline syrup market all over the globe.
Market Coverage
Segment Covered-
Regions covered-
Competitive Landscape: Glenmark Pharmaceuticals Ltd., Cadila Pharmaceuticals Ltd., and Ranbaxy Laboratories Ltd., among others.
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Doxofylline Syrup Market Report by Segment
By Product
Global Doxofylline Syrup Market Report by Region
North America
Europe
Asia-Pacific
Rest of the World